COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Phase II Study to Evaluate Tariquidar (XR9576), a Selective MDR-1 Inhibitor, in Chemotherapy Resistant Advanced Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00048633
Recruitment Status : Completed
First Posted : November 6, 2002
Last Update Posted : May 23, 2012
Information provided by (Responsible Party):
QLT Inc.

Brief Summary:

The primary objective of this phase II study is to assess if XR9576, a selective MDR-1 inhibitor, is able to reverse primary doxorubicin or taxane resistance in advanced breast cancer. Clinical activity will be measured by objective tumor response rates observed after treatment with XR9576 in combination with taxane or anthracycline containing chemotherapy in patients previously resistant to the same agent(s).

The secondary objectives of the study are to assess the biological activity of XR9576 and evaluate MDR-1 expression in these tumors. The MDR-1 inhibitory activity of XR9576 will be evaluated by serial sestamibi scans of the tumor. MDR-1 expression will be detected by immunohistochemistry.

Condition or disease Intervention/treatment Phase
Breast Neoplasms Drug: Chemotherapy Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 30 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : November 2001
Actual Primary Completion Date : June 2003
Actual Study Completion Date : June 2003

Arm Intervention/treatment
Experimental: Tariquidar Drug: Chemotherapy

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Histologically proven breast cancer with primary resistance to anthracyclines (doxorubicin, epirubicin) or taxane (paclitaxel, docetaxel) or both. Primary chemotherapy resistance is defined for the purpose of this protocol as any of the following:

    1. Progression after a minimum of 1 cycles of therapy, or
    2. Stable disease after a minimum of 2 cycles of therapy or,
    3. Relapse within 6 months after completion of an anthracycline or/and taxane containing chemotherapy regimen.
  • Patients with anthracycline/taxane resistance INOPERABLE, locally advanced breast cancer are eligible.
  • Patients must have measurable disease as defined by the RECIST criteria in their breast/nodal regions or at a distant organ site(s).
  • There is no limit on prior hormonal therapies but only one prior chemotherapy for metastatic breast cancer is allowed.
  • Patients may receive concomitant bisphosphonate therapy for bone metastasis.
  • Patients may continue Herceptin if it has previously been started. Herceptin cannot be added to the chemotherapy regimen as a new agent at the same time when XR9576 is initiated.
  • Patients much have recovered from acute toxic effects of any prior therapy.
  • Zubrod performance status less than or equal to 2.
  • Adequate bone marrow function: platelets greater than or equal to 100,000/mm3, ANC greater than or equal to 1500 cells/mm3, hemoglobin greater than or equal to 8g/dl.
  • Normal renal function: creatinine less than or equal to 2.0 mg/dl. Adequate liver function: bilirubin less than or equal to 1.5 mg/dl. Transaminase (SGOT) and alkaline phosphatase must be less than or equal to 1.5 x of the upper limit of normal in the absence of bone or liver metastasis, or less than or equal to 2.5 x of the upper limit of normal in the presence of radiologically apparent liver metastasis or bone metastasis, respectively.
  • Female patients must be of non-lactating and using adequate contraception if premenopausal. Beta-HCG will be checked in premenopausal patients if clinically indicated.
  • Patients with brain metastases whose disease remained stable for more than 3 months after completing therapy to the brain are eligible.
  • Written informed consent.

Exclusion criteria:

  • More than 1 chemotherapy regimen for metastatic breast cancer.
  • Patients who relapsed more than 6 months after completion of anthracycline or taxane therapy.
  • Current treatment with a non-taxane, non-anthracycline based chemotherapy.
  • Uncontrolled psychiatric, or social (addictive) disorders that would preclude obtaining informed consent or patient participation in the study.
  • Clinical contraindication of continued anthracycline or taxane therapy. For patients who show primary resistance to anthracyclines this includes greater than 300 mg/m2 maximum life-time cumulative dose of doxorubicin, symptomatic heart failure, history of heart failure, recent myocardial infarction (less than 6 months) or left ventricular ejection fraction below normal range. For patients with primary resistance to taxanes, persistent grade 2 or greater neuropathy (neuropathy that interferes with function).
  • Patients with operable primary breast cancer are not eligible.
  • Patients who have developed primary resistance to the chemotherapy combination of doxorubicin/docetaxel.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00048633

Layout table for location information
United States, Florida
Florida Oncology Associates
Jacksonville, Florida, United States, 32207-5905
United States, Indiana
Medical Center of Vincennes
Vincennes, Indiana, United States, 47591
United States, Texas
Arlington Cancer Center
Arlington, Texas, United States, 76012
MD Anderson Cancer Center
Houston, Texas, United States, 77030-4009
Sponsors and Collaborators
QLT Inc.
Layout table for investigator information
Study Director: Graeme R Boniface Sponsor GmbH
Layout table for additonal information
Responsible Party: QLT Inc. Identifier: NCT00048633    
Other Study ID Numbers: TQD BRST 001
First Posted: November 6, 2002    Key Record Dates
Last Update Posted: May 23, 2012
Last Verified: May 2012
Keywords provided by QLT Inc.:
Chemotherapy resistance advanced breast cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases